Работайте офлайн с приложением Player FM !
Compounded GLP1s
Manage episode 412652308 series 2931422
Shortages, access, and cost have led to compounding GLP1s, which has created confusion and misinformation for patients and healthcare providers. Join us as we discuss this practice and delve into what you need to know as a healthcare provider.
THE GAMECHANGER: The advent of GLP1s is a true GameChanger in the health of patients with diabetes, cardiovascular diseases, and obesity, and has led to access issues for manufactured products.
Guests
Tenille Davis, PharmD, RPh
Chief Advocacy Officer
Alliance for Pharmacy Compounding
Scott Brunner, CAE
CEO
Alliance for Pharmacy Compounding
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
https://a4pc.org/advocacy/educating-prescribers/
https://a4pc.org/advocacy/statements-and-other-resources/
https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-March-2024.pdf
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Review criteria for compounding drugs on the FDA drug shortage list.
2. Discuss the facts and misinformation surrounding compounded GLP1 medications.
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-145-H01-P
Initial release date: 04/15/2024
Expiration date: 04/15/2025
Additional CPE details can be found here.
Разделы
1. Compounded GLP1s (00:00:00)
2. Compounding and GLP-1s in Healthcare (00:00:08)
3. Drug Shortages (00:08:14)
4. Concerns About Compounded Drugs and Telermedicine (00:18:23)
5. Compounding Sublingual Semaglutide for Patients (00:32:22)
6. Clarifying Compounding Pharmacies and Education (00:40:54)
292 эпизодов
Manage episode 412652308 series 2931422
Shortages, access, and cost have led to compounding GLP1s, which has created confusion and misinformation for patients and healthcare providers. Join us as we discuss this practice and delve into what you need to know as a healthcare provider.
THE GAMECHANGER: The advent of GLP1s is a true GameChanger in the health of patients with diabetes, cardiovascular diseases, and obesity, and has led to access issues for manufactured products.
Guests
Tenille Davis, PharmD, RPh
Chief Advocacy Officer
Alliance for Pharmacy Compounding
Scott Brunner, CAE
CEO
Alliance for Pharmacy Compounding
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
https://a4pc.org/advocacy/educating-prescribers/
https://a4pc.org/advocacy/statements-and-other-resources/
https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-March-2024.pdf
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Review criteria for compounding drugs on the FDA drug shortage list.
2. Discuss the facts and misinformation surrounding compounded GLP1 medications.
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-145-H01-P
Initial release date: 04/15/2024
Expiration date: 04/15/2025
Additional CPE details can be found here.
Разделы
1. Compounded GLP1s (00:00:00)
2. Compounding and GLP-1s in Healthcare (00:00:08)
3. Drug Shortages (00:08:14)
4. Concerns About Compounded Drugs and Telermedicine (00:18:23)
5. Compounding Sublingual Semaglutide for Patients (00:32:22)
6. Clarifying Compounding Pharmacies and Education (00:40:54)
292 эпизодов
Все серии
×Добро пожаловать в Player FM!
Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.